Day: August 30, 2022

Optimi Health Enters Into International Collaborative Research and Supply Agreement With Promises Innovative Recovery Center

Company encouraged by medicinal and therapeutic regulatory developments in Costa Rica Z Strain Psilocybe cubensis Optimi Health, Z Strain Psilocybe...

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

ISELIN, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch...

error: Content is protected !!